Network origin in Amy P. Sing first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
| Subsidiary | Pharmaceuticals: Major | 8 | |
| Public Company | Biotechnology | 4 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Amy P. Sing via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
| AMGEN INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Biotechnology | Corporate Officer/Principal Corporate Officer/Principal | |
Immunex Corp.
 Immunex Corp. BiotechnologyHealth Technology Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovation | Biotechnology | Chief Tech/Sci/R&D Officer | |
| BIOGEN INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| Rochester Christian University | College/University | Undergraduate Degree | |
| ARRAY TECHNOLOGIES, INC. | Pharmaceuticals: Major | Director/Board Member | |
| BRAINSTORM CELL THERAPEUTICS INC. | Biotechnology | Public Communications Contact | |
Anadys Pharmaceuticals, Inc.
 Anadys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Anadys Pharmaceuticals, Inc. develops and manufactures novel small molecule medicines. It engages in developing novel medicines in the areas of hepatitis C and oncology. The firm develops ANA598, a direct-acting antiviral for the treatment of hepatitis C. The company was founded by Stelios B. Papadopoulos and Kleanthis G. Xanthopoulos in 1992 and is headquartered in Little Falls, NJ. | Pharmaceuticals: Major | Director/Board Member | |
| IRONWOOD PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member | |
| AC IMMUNE SA | Pharmaceuticals: Major | Chairman | |
| STEMLINE THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member | |
| DERMATA THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member | |
| OVID THERAPEUTICS INC. | Pharmaceuticals: Major | Director/Board Member | |
Genesis Research & Development Corp. Ltd.
 Genesis Research & Development Corp. Ltd. Financial ConglomeratesFinance Genesis Research & Development Corp. Ltd. operates as a development stage company. Previously, it was a technology investment company that builds a broad therapeutic development platform targeting immune disorders and cancer and a novel single stranded gene silencing technology using the RNAi mechanism. The company was founded by James Douglas Watson in 1994 and is headquartered in Auckland, New Zealand. | Financial Conglomerates | Corporate Officer/Principal | |
| Humboldt State University | College/University | Undergraduate Degree | |
Cornell University
 Cornell University Other Consumer ServicesConsumer Services Cornell University is an educational institution that offers undergraduate and post graduate programs. It was founded in 1865 and is based in Ithaca, NY. | College/University | Doctorate Degree Undergraduate Degree | |
| State University of New York at Buffalo | College/University | Doctorate Degree | |
| University of Louisiana at Lafayette | College/University | Undergraduate Degree | |
| University of Scranton | College/University | Graduate Degree | |
Ascenta Therapeutics, Inc.
 Ascenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ascenta Therapeutics, Inc. engages in the discovery and development of medicines for cancer. Its core technology consists of agents designed to re-establish the natural program of apoptosis (cell death) in abnormal cancer cells. Its has three small molecule programs against distinct apoptosis targets: Bcl-2 (AT-101 – an oral pan-Bcl2 inhibitor), IAP (AT-406 – an oral multi-IAP inhibitor) and HDM2. The company was founded by Dajun Yang, Marc E. Lippman, and Shaomeng Wang on June 5, 2006 and is headquartered in Malvern, PA. | Pharmaceuticals: Major | Director/Board Member Founder | |
The University of Texas M.D. Anderson Cancer Center
 The University of Texas M.D. Anderson Cancer Center Other Consumer ServicesConsumer Services The University of Texas M.D. Anderson Cancer Center provides cancer patient care, research, and prevention for cancer. The firm also provides education for undergraduate and graduate students, trainees, professionals, employees and the publics. The company was founded in 1941 and is headquartered in Houston, TX. | Other Consumer Services | Corporate Officer/Principal | |
| MEDIVATION INC | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| Icahn School of Medicine at Mount Sinai | College/University | Doctorate Degree | |
Fred Hutchinson Cancer Research Center
 Fred Hutchinson Cancer Research Center Miscellaneous Commercial ServicesCommercial Services Fred Hutchinson Cancer Research Center is a non-profit organization which provides research and testing services. The company was founded in 1965 and is headquartered in Seattle, WA. | Miscellaneous Commercial Services | Director/Board Member | |
| REGULUS THERAPEUTICS INC. | Pharmaceuticals: Major | Director/Board Member | |
| University of Massachusetts Lowell | College/University | Undergraduate Degree | |
| Berkeley Law University of California | College/University | Graduate Degree | |
Xenikos BV
 Xenikos BV Medical SpecialtiesHealth Technology Xenikos BV focuses on the development of immunotherapies for the treatment of patients suffering from immune diseases. It is developing a combination of two toxin-loaded anti-T-cell antibodies, T-Guard, as a therapeutic tool for resetting the body's immune system in T-cell mediated diseases. The company was founded by Ypek van Oosterhout in September 2009 and is headquartered in Nijmegen, the Netherlands. | Medical Specialties | Chairman | |
| ADAPTIVE BIOTECHNOLOGIES CORPORATION | Biotechnology | Director/Board Member | |
| CODIAK BIOSCIENCES | Pharmaceuticals: Major | Chief Executive Officer | |
Dendreon Pharmaceuticals, Inc.
 Dendreon Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Dendreon Pharmaceuticals, Inc. discovers, develops and commercializes novel products for the treatment of cancer. The company is headquartered in Olympia, WA. | Medical Specialties | Chief Tech/Sci/R&D Officer | |
| ALPINE IMMUNE SCIENCES, INC. | Biotechnology | Chief Tech/Sci/R&D Officer | |
Cygnal Therapeutics, Inc.
 Cygnal Therapeutics, Inc. BiotechnologyHealth Technology Cygnal Therapeutics, Inc. develops drugs for cancer, immunological diseases and regenerative processes. The company was founded by Noubar Afeyan, Avak Kahvejian and Jordi Mata-Fink in 2017 and is headquartered in Cambridge, MA. | Biotechnology | Director/Board Member | |
Cellenkos, Inc.
 Cellenkos, Inc. Pharmaceuticals: MajorHealth Technology Cellenkos, Inc. is a clinical biotechnology company. It focuses on umbilical cord blood derived T-regulatory cellular therapies for treating autoimmune diseases and inflammatory disorders. The company was founded by Simrit Parmar in September 2016 and is headquartered in Houston, TX. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
Chinook Therapeutics U.S., Inc.
 Chinook Therapeutics U.S., Inc. Information Technology ServicesTechnology Services Chinook Therapeutics U.S., Inc. operates as a development stage company. The company is headquartered in Seattle, WA. | Information Technology Services | Chief Executive Officer | |
| STRUCTURE THERAPEUTICS INC. | Miscellaneous Commercial Services | Director/Board Member | |
| CHINOOK THERAPEUTICS, INC. | Pharmaceuticals: Major | Chief Executive Officer | |
| ATARA BIOTHERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member |
Statistics
International
| United States | 46 |
| Netherlands | 3 |
| Switzerland | 2 |
| New Zealand | 2 |
| Canada | 2 |
Sectoral
| Health Technology | 34 |
| Consumer Services | 11 |
| Commercial Services | 4 |
| Finance | 3 |
| Distribution Services | 2 |
Operational
| Director/Board Member | 55 |
| Corporate Officer/Principal | 29 |
| Chief Tech/Sci/R&D Officer | 20 |
| Independent Dir/Board Member | 18 |
| Undergraduate Degree | 12 |
Most connected contacts
| Insiders | |
|---|---|
| Louis C. Bock | 27 |
| Douglas Williams | 25 |
| Mark P. Colonnese | 14 |
| Marc Lippman | 14 |
| Eric Dobmeier | 14 |
| Andrew Sandler | 12 |
| William F. Hahne | 7 |
| Michael Garrison | 6 |
| Larry K. Benedict | 6 |
| Charles Smith | 4 |
| Tara Sadeghi | 4 |
| Joseph Petroziello | 4 |
- Stock Market
- Insiders
- Amy P. Sing
- Company connections
